|Bid||2.800 x 0|
|Ask||2.830 x 0|
|Day's Range||2.750 - 2.830|
|52 Week Range||2.440 - 4.070|
|Beta (5Y Monthly)||0.86|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 30, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.44|
Subscribe to Yahoo Finance Plus to view Fair Value for 1672.HKLearn more
Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672), announces today that the latest clinical and preclinical data of four NASH programs (ASC40/TVB-2640 co-authored with Sagimet Biosciences Inc., ASC41, ASC42 and ASC43F) will be presented in oral or poster presentation at The Liver Meeting® 2021 of American Association for the Study of Liver Diseases (AASLD). The Liver Meeting® is one of the world's premier meeting on liver disease and will be held during November
Ascletis Pharma Inc. (HKEX: 1672) announces today that the results of Phase IIa trial of subcutaneously administered PD-L1 antibody ASC22 (Envafolimab) in patients with chronic hepatitis B (CHB) will be presented in oral parallel session at The Liver Meeting® 2021 by American Association for the Study of Liver Diseases (AASLD). The Liver Meeting® by AASLD is one of the world's premier meetings on liver disease and will be held during Nov.12-15 this year.
Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), today announces positive topline results from the U.S. Phase I trial of drug-drug interactions in healthy subjects and pharmacokinetics (PK) in patients with non-alcoholic fatty liver disease (NAFLD) for ASC41 oral tablets, a liver-targeted prodrug. ASC41 is mainly metabolized by CYP3A4 to form an active metabolite ASC41-A, a selective thyroid hormone receptor beta (THRβ) agonist.